Clinical findings of Talaromyces marneffei infection among patients with anti-interferon-γ immunodeficiency: a prospective cohort study

BMC Infect Dis. 2021 Jun 19;21(1):587. doi: 10.1186/s12879-021-06255-9.

Abstract

Background: Talaromyces marneffei (T. marneffei) infection has been associated with adult-onset immunodeficiency due to anti-IFN-γ autoantibodies. We aimed to investigate the clinical features of non-HIV-infected patients with T. marneffei infection in southern China.

Methods: Between January 2018 and September 2020, we enrolled patients with T. marneffei infection who were HIV-negative (group TM, n = 42), including anti-IFN-γ autoantibody-positive (group TMP, n = 22) and anti-IFN-γ autoantibody-negative (group TMN, n = 20) patients and healthy controls (group HC, n = 40). Anti-IFN-γ autoantibodies were detected by ELISA. Clinical characteristics and clinical laboratory parameters were recorded.

Results: Compared with anti-IFN-γ autoantibody-negative patients with T. marneffei infection, anti-IFN-γ autoantibody-positive patients did not have underlying respiratory disease; more frequently exhibited dissemination of systemic infections with severe pleural effusion; had higher WBC counts, C-reactive protein levels, erythrocyte sedimentation rates, and neutrophil and CD8+ T cell counts; had lower hemoglobin levels; and were more likely to have other intracellular pathogen infections. Most of these patients had poor outcomes despite standardized antimicrobial therapy.

Conclusion: T. marneffei-infected patients with higher anti-IFN-γ autoantibody titers have more severe disease and complex clinical conditions.

Keywords: Anti-IFN-γ autoantibodies; Clinical features; Clinical outcome; Talaromyces marneffei.

MeSH terms

  • Adult
  • Autoantibodies / blood
  • Female
  • Humans
  • Immunologic Deficiency Syndromes / etiology*
  • Interferon-gamma / immunology*
  • Male
  • Middle Aged
  • Mycoses / immunology*
  • Prospective Studies
  • Severity of Illness Index

Substances

  • Autoantibodies
  • Interferon-gamma

Supplementary concepts

  • talaromycosis